Figure A.10. ISHLT Registry of annualized heart transplant volume.

The REMATCH primary end-point was set at a 33% improvement in survival for LVAD patients who are not eligible for cardiac transplantation over two years. The goal was for patients to experience improved function without a decrement in quality of life compared to the randomized control group. Cost and cost-effectiveness will also be analyzed as the data becomes available.

The LVAD patients demonstrated a 48% improvement in survival (Fig. A. 11), significant functional gains, and suggestions of improved quality of life (Fig. A. 12), compared with patients receiving optimal medical management (OMM). The LVAD patients also experienced increased adverse events of infections, bleeding, and technical device problems (Table A.3). At two years, updated data (not shown) showed a 200% increase in survival but also a high number of device failures.


Figure A.11. The LVAD patient improvements in survival.

Figure A.12. The LVAD patient improvement in quality of life.

Table A.3. LVAD Patients' Adverse Events

0 0

Post a comment